SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-004788 to ARTELO BIOSCIENCES, INC. (ARTL)

ARTELO BIOSCIENCES, INC.
Date: May 11, 2026 · CIK: 0001621221 · Accession: 0000000000-26-004788

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295537

Date
May 11, 2026
Author
Gregory D. Gorgas
Form
UPLOAD
Company
ARTELO BIOSCIENCES, INC.

Letter

May 11, 2026 Gregory D. Gorgas Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed May 04, 2026 File No. 333-295537 Dear Gregory D. Gorgas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amanda I. Hawthorne, Esq.

Show Raw Text
May 11, 2026
Gregory D. Gorgas
Chief Executive Officer
Artelo Biosciences, Inc.
505 Lomas Santa Fe, Suite 160
Solana Beach, CA 92075
Re: Artelo Biosciences, Inc.
Registration Statement on Form S-3
Filed May 04, 2026
File No. 333-295537
Dear Gregory D. Gorgas:
 This is to advise you that we have not reviewed and will not review your registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
 Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Amanda I. Hawthorne, Esq.